uniQure (UQ1) AI Stock Analysis

2 Followers

uniQure

(XETRA:UQ1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Regulatory ProgressPriority regulatory review and U.K. validation materially advance AMT-130 toward potential commercialization in major markets. These milestones reduce development uncertainty, support commercial planning, and could establish a durable revenue platform if the therapy ultimately receives approval.

Negative Factors

Persistent Cash BurnPersistent operating and free-cash-flow deficits show that uniQure is not currently self-funding and must spend heavily ahead of potential product revenue. Continued burn can reduce liquidity over time and increase dependence on successful development, commercialization, or external financing.

uniQure (UQ1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.72B
Dividend Yield: ―
Average Volume (3M): 373
Price to Earnings (P/E): -6.9
Beta (1Y): 1.66
Revenue Growth: 22.37%
EPS Growth: 23.10%
Country: Germany
Employees: 221
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

uniQure Business Overview & Revenue Model

Company Description

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding....

uniQure Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:0.48%|Next Earnings Date:Mar 01, 2027

Earnings Call SentimentPositive

The call conveyed strong positive momentum, led by FDA priority review and MHRA validation for AMT-130, statistically significant disease-progression slowing, progress toward the confirmatory study, commercial preparation and a cash runway into 2030. The company also reported higher operating expenses, mixed early AMT-260 responses, a prior AMT-191 enrollment pause and remaining uncertainty around regulatory review, access and launch capacity. Highlights significantly outweighed the lowlights.

Positive Updates

AMT-130 BLA Accepted for Priority Review

The FDA accepted uniQure's biologics license application for AMT-130 and granted priority review, with a target PDUFA date of May 1, 2027. The MHRA also validated the company's marketing authorization application in the United Kingdom. These are the first such marketing applications for a disease-modifying Huntington's disease therapy.

Negative Updates

Operating Expenses Increased

Third-quarter research and development expenses increased to $35.5 million from $34.4 million, up $1.1 million or approximately 3.2%. The increase was primarily driven by a $3.6 million increase in employee and contractor-related expenses, including share-based compensation, partially offset by a $2.3 million decrease in direct R&D expenses.

Company Guidance

uniQure expects the AMT-130 confirmatory study to be a global randomized study with a 2:1 ratio of AMT-130 high dose to standard of care, approximately 200 patients, and TFC at 36-month as the primary endpoint; patient screening is expected to begin by the end of this year, with the study well underway by the May 1, 2027 PDUFA date, and standard-of-care participants offered AMT-130 in a separate open-label study after 36-month. The company expects updated AMT-260 and AMT-191 data in the first half of 2027, its core commercial team fully in place by early next year, and a potential U.S. launch in 2027; it expects to be north of 15 treatment centers at launch, although whether that could be 25 or 30 has not been defined, with center capacity ranging from 2 a week to one a month. Cash, cash equivalents and investment securities are expected to fund operations into 2030, and uniQure expects to provide a day 120 safety update.

uniQure Risk Analysis

uniQure disclosed 70 risk factors in its most recent earnings report. uniQure reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

uniQure Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:UQ1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AGIO	55Neutral	$1.90B	-5.19	-34.63%	―	214.44%	9.13%
AMLX	53Neutral	$3.97B	-22.39	-41.54%	―	―	19.61%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BCRX	49Neutral	$1.94B	-5.67	94.36%	―	60.30%	-3028.57%
PHVS	46Neutral	$2.39B	-11.41	-61.24%	―	―	9.42%
IMNM	39Underperform	$2.20B	-7.20	-51.33%	―	-100.00%	11.09%

* Healthcare Sector Average

Performance Comparison

DE:UQ1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:UQ1	uniQure N.V.	20.85	-4.66	-18.27%
BCRX	BioCryst Pharmaceuticals	7.65	0.75	10.87%
AGIO	Agios Pharmaceuticals	32.82	-9.72	-22.85%
IMNM	Immunome, Inc.	19.07	2.56	15.51%
PHVS	Pharvaris N.V.	34.18	9.92	40.89%
AMLX	Amylyx Pharmaceuticals, Inc.	31.80	19.38	156.04%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

uniQure AI Stock Analysis